© Reuters. FILE PHOTO: The Novartis logo is seen at the Swiss drugmaker’s cell and gene therapy plant in Stein, Switzerland, November 28, 2019. REUTERS / Arnd Wiegmann / File Photo
ZURICH (Reuters) – Swiss drugmaker Novartis said on Tuesday it had acquired gene therapy specialist Arctos Medical for an undisclosed amount, in a bid to step up efforts to find treatments for severe vision loss.
Arctos’ technology is a potential way to treat hereditary retinal dystrophies (IRD) and other diseases involving loss of photoreceptors, such as age-related macular degeneration (AMD).
Existing gene therapy treatments aim to correct a specific gene, so that only a small number of patients can benefit, Novartis said. Arctos technology is not limited to a specific gene and has the potential to treat many forms of IRD, he said.
IRD affects more than 2 million people worldwide and often results in complete blindness. AMD, meanwhile, affects around 170 million people worldwide, Novartis said.
The acquisition underscores its commitment to using optogenetic-based therapies to restore vision in patients with advanced blindness, the company said.
“Optogenetics is emerging as a promising therapeutic approach that could restore sight to legally blind patients,” Jay Bradner, president of the Novartis Institutes for Biomedical Research, said in a statement.
Fusion media or anyone involved with Fusion Media will accept no responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.